RxDoctor Payments Data

Karen Smith, MD

Internal Medicine · Lafayette, LANPI 1942293329

Payments from drug & device makers

$2,053in general payments, 2019–2025

Across 48 payments — averaging $42.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$730
  • Lilly USA, LLC$362
  • Abbott$254
  • AbbVie$168
  • Bayer$129
  • Amgen$114
  • plus $297 from 8 others

What the payments were for

  • Food & beverage$1,79387%
  • Education$70%
  • Other$25412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,053 in reported general payments places this provider in the 75th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$105,523
Medicare patients
189
Services billed
1,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide84$87,929
TrulicityDulaglutide41$46,764
RybelsusSemaglutide43$44,816
OzempicSemaglutide41$44,578
JardianceEmpagliflozin33$34,959
EliquisApixaban31$25,891
LinzessLinaclotide15$10,982
TrintellixVortioxetine Hydrobromide22$10,677
Repatha SureclickEvolocumab18$10,107
Spiriva RespimatTiotropium Bromide17$8,538
MyrbetriqMirabegron11$8,106
Vilazodone Hcl24$3,738
Rosuvastatin Calcium189$3,643
SymbicortBudesonide/Formoterol Fumarate14$3,270
Diltiazem 12hr ErDiltiazem Hcl12$2,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$362$135,760139 claims
Novo NordiskRybelsus, Ozempic$730$89,39484 claims
Boehringer IngelheimJardiance, Spiriva Respimat$98$43,49750 claims
PfizerEliquis$76$25,89131 claims
AbbVieLinzess, Synthroid$168$13,25039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →